New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional diet and exercise regimens.
Research printed in a leading medical journal demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing these treatments need to be informed of the risk of quick rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight in about one and a half years.
Analyzing Approaches
The study, which looked at 37 of trials involving thousands of participants, compared the outcomes of the injectable medications with older methods.
Scientists emphasize that people who lose weight through dieting generally see a slower weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Nutrition scientists suggest the way of the drugs is key to understanding the accelerated regain.
These medications copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
The NHS advise the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the treatment should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," comparing it to managing diseases like hypertension.
User Testimonies
Users who have discontinued the jabs explain a powerful resurgence of cravings.
"It was like a switch that goes on and I was suddenly extremely hungry," recalled a patient.
This challenge is exacerbated if users have not developed permanent lifestyle or habit modifications during therapy.
Significant Use
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is more common among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent solution and long-term success hinges on integrated behavioural management.
